Abstract
Background Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.
Objective This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through the last full week of August 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and August 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.
Results We included 642,821 hospitalizations of 592,200 unique patients who tested positive for a respiratory virus between October 01, 2019 and August 25, 2024. Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. COVID-associated hospitalizations saw a slight decrease of 2.9%, while influenza-associated hospitalizations dropped significantly by 57.4%. Other respiratory viruses, including HMPV and RSV, reported no hospitalizations during this period, although rhinovirus-associated hospitalizations increased by 61.7%. In the last week of August 2024, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations. For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising through August (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity.
Discussion The data indicates that respiratory virus-associated hospitalizations have stabilized at low levels during August 2024, following a trend of decreasing rates observed earlier in the year. The notable decrease in influenza-associated hospitalizations suggests a continued decline in this virus’s impact. In contrast, the increase in rhinovirus-associated hospitalizations highlights its growing significance in the current respiratory virus landscape.
Overall populationFor the overall population, the rate of hospitalizations associated with respiratory viruses remained unchanged in August 2024 compared to July 2024. The slight decrease in COVID-associated hospitalizations (-2.9%) and the significant drop in influenza-associated hospitalizations (-57.4%) counterbalanced the significant increase in rhinovirus-associated hospitalizations (+61.7%). In the last week of August, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations.
For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity.
Infants and children (age 0-4)In the population aged 0-4 years, respiratory virus-associated hospitalizations increased significantly by 40.6% throughout August 2024. This rise was primarily driven by increases in rhinovirus-associated hospitalizations, which rose by 80.9%. In the last week of August, 2.4% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus being the largest contributor at 1.8%.
For August, test positivity for COVID is high (19.4%), but peaked in August and is falling (-7.5%). Test positivity for rhinovirus is high (42.1%) and rising (+30.7%). For other viruses, test positivity is lower, with parainfluenza having the next highest test positivity at 3.3%. No other viruses have a rising test positivity.
Older adults (age 65 and over)Among older adults (age 65 and over), there was a slight decrease of 4.7% in hospitalizations associated with respiratory viruses in August 2024 compared to July 2024. COVID-associated hospitalizations remained stable, while influenza-associated hospitalizations saw a significant decline of 62.9%. In the last week of August, respiratory virus-associated hospitalizations accounted for 3.4% of all hospitalizations in this age group, with COVID remaining a consistent contributor.
For August, test positivity for COVID is high (21.8%) but falling (-4.1%) compared to the last week of July. Rhinovirus has the next highest test positivity at 4.0%, which has been rising throughout August (+20.6%).
Competing Interest Statement
All authors are employees of Truveta, Inc
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Para. 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We updated the data till end of August 2024.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
